Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘As bad as it gets’: Donald Trump’s New York business empire imperilled by fraud ruling
    • ‘Princess of Uzbekistan’ indicted as crime syndicate boss
    • Armenians ‘lose motherland’ in blow to Russia’s influence abroad
    • Obesity drugmaker’s expansion raises dominance worries for Denmark
    • Sweden turns to military to help police combat gang crime
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • US private equity firm takes stake in Liverpool Football Club
      • Former Goldman and Blackstone employee charged with insider trading
      • Adani switches UK auditor to firm with four partners  
      • Abu Dhabi group IHC sells out of two Adani companies
      • Dealmaking languishes at decade low on private equity drought
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • News updates from September 28: US mortgage rates hit 22-year high, Evergrande chair under ‘mandatory measures’
      • European bond market hit by Italy’s plans for higher borrowing
      • A power grab against private equity threatens the US economy
      • Former Goldman and Blackstone employee charged with insider trading
      • Live news: UK mortgage approvals fall to lowest level in six months
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A power grab against private equity threatens the US economy
      • South Africans’ support for Russia is rooted in misplaced nostalgia
      • What happened to the savings squirrelled away during the pandemic?
      • The promise — and peril — of generative AI
      • A strategy for hard-pressed consultants
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Success is more complicated than one exceptional individual
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
      • What Burberry taught me about the marketed mind
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Why Linda Yaccarino took on the wildest job in Silicon Valley
      • Horizon 22 trumps the Shard to become London’s highest viewpoint (and it’s free)
      • Democracies need to work quicker and smarter. Here’s what that might look like 
      • Booker Prize 2023: the shortlisted titles reviewed
      • 64 Goodge Street: ‘A gorgeous room’ – restaurant review
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jamie Smyth

    US Energy Editor

    Jamie Smyth is the US energy editor of the Financial Times. He is based in the New York bureau and manages a team covering the US oil, gas and renewables sectors. He previously worked as the FT’s US pharmaceutical correspondent, Australia correspondent and Ireland correspondent.

    Prior to the FT he reported for The Irish Times newspaper in Brussels and Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 24 September, 2023
      InterviewEU energy
      Top EU energy official says US gas will be needed for decades

      Bloc will have a ‘need for American energy’ says Ditte Juul Jørgensen

      Workers at the Cheniere Sabine Pass liquefaction facility in Cameron, Louisiana
    • Wednesday, 20 September, 2023
      FT News Briefing podcast13 min listen
      Oil prices are not a barrel of fun

      Instacart shares close up 12% after public market debut

    • Wednesday, 20 September, 2023
      US presidential election 2024
      DeSantis leads charge to pry Texas oil donors from Trump

      Onetime supporters of ex-president are hunting for an alternative to roll back Biden’s green agenda

      Florida governor Ron DeSantis addresses a crowd in Texas
    • Monday, 18 September, 2023
      The Big Read
      The Biden administration takes on the US drugs industry

      New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer

    • Sunday, 17 September, 2023
      Oil & Gas industry
      California accuses Big Oil of covering up climate change risks in lawsuit

      Civil action seeks damages to help mitigate costs of global warming caused by fossil fuels

      Firefighters spray water in the Sequoia National Forest, California
    • Friday, 15 September, 2023
      ExplainerOil
      Why oil is back to $90 a barrel

      Saudi Arabia and Russia have curtailed supplies in the face of record global demand

      Pump jack in Loco Hills region, New Mexico
    • Thursday, 14 September, 2023
      Energy Source
      Joe Biden is stuck on the gasoline price elevator Premium content

      Also in today’s newsletter, the projected cost of hitting net zero

      Petrol prices over $5 a gallon at a gas station
    • Tuesday, 5 September, 2023
      Illumina Inc
      Illumina appoints new CEO after battle with investors

      Biotech has been criticised for closing its $8bn acquisition of cancer test company Grail without regulatory approval

      Illumina’s global headquarters in San Diego, California
    • Sunday, 3 September, 2023
      Vivek Ramaswamy
      Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant

      Biotech company rejects founder and Republican presidential hopeful’s criticism of US drug regulator

      Former biotech executive Vivek Ramaswamy in the spin room following the Republican primary debate in Milwaukee, Wisconsin
    • Tuesday, 29 August, 2023
      US politics & policy
      US targets 10 drugs for pricing negotiations in crackdown on costs

      Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades

      A pharmacist holds a bottle of the drug Eliquis, sold by Bristol Myers Sqibb and Pfizer
    • Tuesday, 29 August, 2023
      3M Co
      3M agrees historic $6bn settlement over combat earplug lawsuits

      Post-it note maker to resolve mass US tort litigation brought by more than 250,000 military veterans

      3M signage outside the company’s plant in Ames, Iowa
    • Monday, 28 August, 2023
      FT News Briefing podcast10 min listen
      In search of a new economic playbook

      Chinese corporate earnings reports this week are forecast to log poor performance

    • Sunday, 27 August, 2023
      News in-depthEU economy
      Ireland seeks to lure life science investment despite corporate tax rise

      Dublin believes that the country’s skill base will attract pharma and medical companies

    • Saturday, 26 August, 2023
      News in-depthUS presidential election 2024
      From biotech booster to Republican contender: the rise of Vivek Ramaswamy

      Presidential candidate makes polling gains by capitalising on image as successful businessman

      Vivek Ramaswamy on stage during the TV debate
    • Friday, 25 August, 2023
      AstraZeneca PLC
      AstraZeneca sues US government over drug price reforms

      Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines

      Assembly line at AstraZeneca manufacturing plant
    • Tuesday, 22 August, 2023
      Pharmaceuticals sector
      Use of horseshoe crabs’ blue blood puts pharma groups under scrutiny

      BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances

      Person holds a horseshoe crab
    • Sunday, 13 August, 2023
      Drugs research
      Eli Lilly achieves hard-won success with Alzheimer’s and obesity drugs

      US pharmaceutical group says it wants to become the first trillion dollar healthcare company

      A pharmacist displays a box of Eli Lilly’s Mounjaro diabetes and weight loss treatment
    • Thursday, 10 August, 2023
      Purdue Pharma LP
      Supreme Court halts $6bn Purdue opioid settlement in blow to Sacklers

      Justices will consider whether the law permits the waiver of future claims against parties not in bankruptcy

      A pharmacist holds a bottle of OxyContin
    • Wednesday, 9 August, 2023
      FT News Briefing podcast9 min listen
      The weight-loss drug craze

      US bank stocks stumble after Moody’s cut ratings of midsized lenders

    • Tuesday, 8 August, 2023
      Novo Nordisk AS
      Novo Nordisk’s obesity drug cuts risk of strokes and heart attacks

      Shares in Danish drugmaker and US rival Eli Lilly surge to record highs after positive trial of weight-loss drug

      Injector pens for the Wegovy weight loss drug in a box
    • Wednesday, 2 August, 2023
      Pharmaceuticals sector
      Lawsuit alleges blockbuster weight-loss drugs cause ‘stomach paralysis’

      Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk

      Person holding boxes of Ozempic
    • Tuesday, 25 July, 2023
      Drug prices
      Novartis boss warns US drug pricing reform poses risk to public health

      Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker

      Vas Narasimhan
    • Thursday, 13 July, 2023
      Biotech
      Grail sued by three female ex-employees over ‘toxic work culture’

      Illumina-owned cancer testing group allegedly failed to deal with accusations of inappropriate behaviour and racism

      Illumina’s offices in San Diego, California
    • Monday, 3 July, 2023
      The Big Read
      How a Swedish start-up reignited the search for an Alzheimer’s drug

      A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise

    • Monday, 26 June, 2023
      Biotech
      Biotech begins human trials of drug designed by artificial intelligence

      Insilico Medicine says trial of lung disease therapy is milestone for generative AI in drug development

      Insilico Medicine founder and chief executive Alex Zhavoronkov and Feng Ren, co-chief and chief science officer, at the company’s AI-powered robotics lab in Suzhou, China
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In